In a landmark development, Schrödinger, Inc. has entered into a multi-target research collaboration and expanded software licensing agreement with Novartis AG, potentially valued at up to $2.5 billion. This strategic alliance aims to leverage Schrödinger’s advanced computational platform to accelerate drug discovery and development across various therapeutic areas. Under the terms of the agreement, Schrödinger […]
Eli Lilly & Co. has faced a dramatic drop in its stock price, tumbling over 10% following a critical earnings report that highlighted missed revenue targets for two of its most anticipated drugs: Mounjaro, a diabetes medication, and Zepbound, a high-profile weight-loss drug. Investors, who had anticipated a robust sales report amid growing demand for […]
AbbVie, the renowned American biopharmaceutical giant, is set to acquire Aliada Therapeutics for a staggering $1.4 billion. The acquisition grants AbbVie control over Aliada’s promising Alzheimer’s treatment, ALIA-1758, and the biotech’s innovative Modular Delivery (MODEL) platform, which could overcome significant barriers in treating neurological disorders, particularly Alzheimer’s disease. Key Drivers Behind the Acquisition AbbVie aims […]
The UK has approved Eli Lilly’s new Alzheimer’s treatment, donanemab, which has shown promise in slowing cognitive decline. However, the National Institute for Health and Care Excellence (NICE) determined it is too costly for widespread use within the NHS. This decision comes despite the Medicines and Healthcare products Regulatory Agency (MHRA) deeming the drug safe […]
Eli Lilly and Company (Lilly) has secured approval from the U.S. Food and Drug Administration (FDA) for its new biologic treatment, EBGLYSS (lebrikizumab-lbkz), for moderate-to-severe atopic dermatitis in adults and children aged 12 and older. This biologic drug is positioned as a first-line treatment option, promising substantial relief for patients whose eczema is not well […]
Eli Lilly and Company (NYSE: LLY) has announced a substantial $1 billion investment to expand its Limerick, Ireland, manufacturing site, which will increase the production of biologic active ingredients, including those for its newly approved treatment for early symptomatic Alzheimer’s disease. Simultaneously, the company unveiled a new $800 million facility expansion in Kinsale, Ireland, which […]
Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal, aimed at enhancing treatment options for inflammatory bowel disease (IBD). This acquisition underscores Lilly’s strategic expansion into the gastroenterology sector. The transaction, valued at $57 per share, is a significant premium over Morphic’s recent stock prices, reflecting […]
In a major strategic move, Eli Lilly and Company (NYSE: LLY) has announced a definitive agreement to acquire Morphic Holding, Inc. (NASDAQ: MORF), a biopharmaceutical company known for its innovative work in developing oral integrin therapies. The acquisition, valued at $57 per share in cash, totals approximately $3.2 billion. This acquisition represents a significant premium […]
The U.S. Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt), an Alzheimer’s treatment developed by Eli Lilly and Company (NYSE: LLY). This treatment, specifically designed for adults with early symptomatic Alzheimer’s disease, includes those with mild cognitive impairment (MCI) and the mild dementia stage of Alzheimer’s, with confirmed amyloid pathology. Priced at $350 million […]
Eli Lilly and Company (NYSE: LLY) has announced promising results from the SURMOUNT-OSA phase 3 clinical trials of tirzepatide, a novel treatment aimed at moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Detailed results, published in The New England Journal of Medicine and presented at the American Diabetes Association’s 84th Scientific Sessions, reveal significant […]